Gamma-PN is under clinical development by GPN Vaccines and currently in Phase II for Streptococcal Pneumonia. According to GlobalData, Phase II drugs for Streptococcal Pneumonia have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gamma-PN’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gamma-PN overview
Gamma-PN vaccine is under development for the prevention of Streptococcal pneumonia. The vaccine candidate is administered intranasal and intramuscular. It is an inactivated, gamma-irradiated and un-encapsulated streptococcus pneumoniae strain Rx1. It is prepared by deletion of the unmarked autolysin gene lytA and with the pneumolysin gene ply replaced with an allele encoding a non-toxic pneumolysoid (PdT) using gamma irradiation to inactivate the bacteria. It was also under development for the treatment pneumonococcal sepsis caused by S. pneumoniae strain.
GPN Vaccines overview
GPN Vaccines, formerly GPN Vaccines, is a clinical-stage company focused on creating vaccines that offer robust protection against bacterial pathogens. It develops vaccines to protect adults and children from the world’s most deadly pathogens. GPN Vaccines lead product Gamma-PN which induce antibodies to all pneumococcal strains. The company’s pipeline product include GPNV-006 which is a randomised, active-controlled, blinded, dose-ranging study of the safety, tolerability, and immunogenicity of Gamma-PN3. GPN Vaccines is headquartered in Griffith, New South Wales, Australia.
For a complete picture of Gamma-PN’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
